James B Dale

Summary

Publications

  1. ncbi request reprint Group A streptococcal vaccines: paving a path for accelerated development
    James B Dale
    University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Vaccine 31:B216-22. 2013
  2. pmc Potential coverage of a multivalent M protein-based group A streptococcal vaccine
    James B Dale
    University of Tennessee Health Science Center, Department of Medicine and Veterans Affairs Medical Center Research Service, Memphis, TN, USA
    Vaccine 31:1576-81. 2013
  3. pmc New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
    James B Dale
    Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Vaccine 29:8175-8. 2011
  4. pmc Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes
    Harry S Courtney
    Department of Medicine, University of Tennessee, Memphis, Tennessee, United States of America
    PLoS ONE 4:e4166. 2009
  5. pmc Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes
    Thomas A Penfound
    Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States
    Vaccine 28:5017-22. 2010
  6. pmc Inactivation of DltA modulates virulence factor expression in Streptococcus pyogenes
    Kathleen H Cox
    Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
    PLoS ONE 4:e5366. 2009
  7. ncbi request reprint Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein
    Harry S Courtney
    Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, TN 38104, USA
    Mol Microbiol 59:936-47. 2006
  8. ncbi request reprint Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center, Department of Medicine, Memphis, TN, USA
    Ann Med 34:77-87. 2002
  9. pmc Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, USA
    Infect Immun 71:5097-103. 2003
  10. pmc Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes
    James B Dale
    Department of Veterans Affairs, The University of Health Science Center, Memphis, TN 38104, USA
    Clin Diagn Lab Immunol 12:833-6. 2005

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Group A streptococcal vaccines: paving a path for accelerated development
    James B Dale
    University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Vaccine 31:B216-22. 2013
    ..Specific recommendations are presented for an accelerated plan leading to the introduction of a broadly protective vaccine designed for deployment in low-, middle-, and high-income countries...
  2. pmc Potential coverage of a multivalent M protein-based group A streptococcal vaccine
    James B Dale
    University of Tennessee Health Science Center, Department of Medicine and Veterans Affairs Medical Center Research Service, Memphis, TN, USA
    Vaccine 31:1576-81. 2013
    ..The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD...
  3. pmc New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
    James B Dale
    Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Vaccine 29:8175-8. 2011
    ..These results indicate that the potential efficacy of the new multivalent vaccine may be greater than predicted based on the "type-specific" M peptides represented...
  4. pmc Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes
    Harry S Courtney
    Department of Medicine, University of Tennessee, Memphis, Tennessee, United States of America
    PLoS ONE 4:e4166. 2009
    ....
  5. pmc Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes
    Thomas A Penfound
    Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States
    Vaccine 28:5017-22. 2010
    ....
  6. pmc Inactivation of DltA modulates virulence factor expression in Streptococcus pyogenes
    Kathleen H Cox
    Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America
    PLoS ONE 4:e5366. 2009
    ..In this study, we have further investigated the effects that mutating dltA has on virulence factor expression in Streptococcus pyogenes...
  7. ncbi request reprint Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein
    Harry S Courtney
    Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, TN 38104, USA
    Mol Microbiol 59:936-47. 2006
    ..This may be a common mechanism for evasion of phagocytosis because Mrp is expressed by approximately half of the clinical isolates of S. pyogenes...
  8. ncbi request reprint Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center, Department of Medicine, Memphis, TN, USA
    Ann Med 34:77-87. 2002
    ..In this review, we present the different molecular mechanisms of adhesion utilized by group A streptococci and how these interactions lead to colonization and invasion...
  9. pmc Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, USA
    Infect Immun 71:5097-103. 2003
    ....
  10. pmc Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes
    James B Dale
    Department of Veterans Affairs, The University of Health Science Center, Memphis, TN 38104, USA
    Clin Diagn Lab Immunol 12:833-6. 2005
    ....
  11. pmc Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections
    Mary A Hall
    Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 72:2507-12. 2004
    ..Our results indicate that intranasal delivery of adjuvanted multivalent M protein vaccines induces protective antibody responses and may provide an alternative to parenteral vaccine formulations...
  12. pmc The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice
    Thomas A Penfound
    Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    J Infect Dis 201:1580-8. 2010
    ..The NH(2)-terminal sequence of the M protein from group A streptococci defines the serotype of the organism and contains epitopes that evoke bactericidal antibodies...
  13. pmc Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci
    James B Dale
    Department of Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 70:2166-70. 2002
    ..Our data also provide convincing evidence that the sagA gene actually encodes the SLS peptide of GAS. The synthetic peptide may prove to be an important component of vaccines designed to prevent GAS infections...
  14. doi request reprint Current status of group A streptococcal vaccine development
    James B Dale
    University of Tennessee Health Science Center, Memphis 38104, USA
    Adv Exp Med Biol 609:53-63. 2008
    ..Successful deployment of safe and effective vaccines to prevent GAS infections and their complications could potentially have a significant impact on the health of millions of people around the world...
  15. ncbi request reprint Mapping the fibrinogen-binding domain of serum opacity factor of group a streptococci
    Harry S Courtney
    Department of Medicine, University of Tennessee, Memphis, TN, USA
    Curr Microbiol 44:236-40. 2002
    ..These data suggest that fibrinogen and fibronectin bind to the same domain within SOF. It remains to be determined whether the binding of fibrinogen to SOF contributes to the virulence of group A streptococci...
  16. doi request reprint The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective
    Gene H Stollerman
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 46:1038-45. 2008
    ..We believe that it is time to refocus newer clinical studies and techniques on achieving early recognition of potentially dangerous, heavily encapsulated strains of GAS for which spread may be prevented...
  17. ncbi request reprint Southern Society for Clinical Investigation Founders' Medal recipient's address
    James B Dale
    University of Tennessee College of Medicine, Memphis, USA
    Am J Med Sci 324:61-6. 2002
  18. ncbi request reprint Presentation of the Southern Society for Clinical Investigation 2002 Founders' Medal to Dr. James B. Dale
    Andrew H Kang
    Department of Medicine, University of Tennessee College of Medicine, Memphis 39163, USA
    Am J Med Sci 324:57-60. 2002
  19. doi request reprint Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage
    Mark E Engel
    From the Department of Medicine, Groote Schuur Hospital and University of Cape Town Department of Clinical Laboratory Sciences, Division of Microbiology, National Health Service and University of Cape Town, Cape Town, South Africa and University of Tennessee Health Science Center, Memphis, TN
    Pediatr Infect Dis J 33:208-10. 2014
    ..Coverage of a 30-valent vaccine is predicted to be 95% of pharyngitis cases in this population at high risk of rheumatic fever. ..